Skip to content
Subscriber Only

Pharma Makes Lobbying Push to Roll Back Seniors' Drug Discounts

  • Drug industry stands to lose $1.9 billion under February law
  • Lobbyists ramping up spending to roll back regulatory changes
Pharmaceutical Manufacture At Russian Drugmaker OAO Pharmstandard
Photographer: Andrey Rudakov/Bloomberg

Pharma giants have been quick to tout their efforts to help the Trump administration rein in runaway drug prices, but behind the scenes the industry has been lobbying furiously to roll back recently mandated medicine discounts for U.S. seniors.

Drug companies are focusing lobbying efforts to use a possible lame-duck session of Congress to peel back a legislative loss they suffered earlier this year, according to people familiar with the efforts. On the line for the drug industry is $1.9 billion next year, according to one estimate. Critics say the effort by the industry has the potential to increase costs for some of the most vulnerable and medically fragile Americans: seniors on Medicare.